All In MedTech

Device Trial Radar · NCT04776031

Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes

Evaluation of the R:GEN Laser System as an Intervention in Subjects With Early Stages of Age Related Macular Degeneration (AMD) for Safety and Exploratory Efficacy Outcomes

Last checked: Nov 20, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Feb 15, 2021

Primary completion

Mar 14, 2023

Study completion Mar 14, 2023

Sponsor

Lead sponsor
Lutronic Vision, IncNot on our public-company list
Sponsor type
Industry
Collaborators
Neuroscience Trials Australia
First posted
Mar 1, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of the R:GEN Laser System in subjects with the early stages of age-related macular degeneration.

Conditions

  • Early Age Related Macular Degeneration (Disorder)

Interventions

  • R:GEN Laser SystemDevice

    Laser Treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To access the safety and tolerability of the R:GEN Laser System in subjects with the early stages of AMD.Time frame: up to 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Eye Research Australia - Royal Victorian Eye & Ear Hospital

    East Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.